From Collection to Infusion: Comprehensive CAR T Treatment and Management Strategies From CAR T Specialists
Panelists discuss how patients and medical teams navigate the complex CAR T therapy journey, from initial referral through cell collection, manufacturing, and infusion, while highlighting crucial monitoring strategies for managing adverse effects such as cytokine release syndrome and neurotoxicity.
Video content above is prompted by the following:
- Could you describe your experience during the referral, CAR T cell collection, manufacturing, and infusion process? How did your care team support you throughout your journey? What resources and communities did you find most supportive as you navigated this process and recovery?
- What is your approach to monitoring and managing patients throughout CAR T collection, manufacturing, and infusion? How do you monitor and manage key CAR T–specific adverse effects such as cytokine release syndrome or neurotoxicity? Do you have any key prophylactic strategies or best practices for optimal patient outcomes and safety?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
